{"id":388035,"date":"2020-11-24T16:08:04","date_gmt":"2020-11-24T21:08:04","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388035"},"modified":"2020-11-24T16:08:04","modified_gmt":"2020-11-24T21:08:04","slug":"vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/","title":{"rendered":"Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>FOSTER CITY, Calif., Nov.  24, 2020  (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on Wednesday, December 2, 2020 at 1:50pm ET.<\/p>\n<p>A live webcast of the fireside chat can be accessed through the Investors &amp; Media section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Yqa1jRWL49rj5bjKhdiYNfCkeIi-UoIs8vVif0X97sHx3ADCHKDryar_n5d7KM-ZuA6xVVZuPcTAGAI2S6djtvRKfVE0XuvukhY-KMekyaA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/investors.vaxcyte.com<\/a>. A replay of the webcast will be available for approximately 30 days following the conference.<\/p>\n<p>\n        <strong>About Vaxcyte<\/strong><br \/>\n        <br \/>Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company\u2019s cell-free protein synthesis platform, comprising the XpressCF\u2122 platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte\u2019s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte\u2019s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). Vaxcyte\u2019s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains, including newly emerging strains responsible for IPD and antibiotic resistance; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HTjxBNfpRC6yvE9D1Tig_jBFcQhGj_ah0m4xqrrLq5i7O3mH0URvh98xEqWpFQQZZBgqbNq1I_stp2-Sbp7aeg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.vaxcyte.com<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Andrew Guggenhime, Chief Financial Officer &amp; Chief Business Officer<br \/>Vaxcyte, Inc.<br \/>650-837-0111<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TgEdTgXmOxO75hj9fU43JuBXZiUzPHh17JmpXgF_PoOpmci4H6nKBNPAJh1iUJpwn-jXd4_8p_A9GtjYPhMBcHcakzStWiBHdfbWR7CVWFw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investors@vaxcyte.com<\/a>\u00a0<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgzOCMzODQyNzg2IzIxOTU4MjQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/dc4ab730-9935-4b3b-bc30-56435d219c76\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FOSTER CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on Wednesday, December 2, 2020 at 1:50pm ET. A live webcast of the fireside chat can be accessed through the Investors &amp; Media section of the Company\u2019s website at http:\/\/investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte Vaxcyte is a next-generation vaccine company seeking to improve &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388035","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FOSTER CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on Wednesday, December 2, 2020 at 1:50pm ET. A live webcast of the fireside chat can be accessed through the Investors &amp; Media section of the Company\u2019s website at http:\/\/investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte Vaxcyte is a next-generation vaccine company seeking to improve &hellip; Continue reading &quot;Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T21:08:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgzOCMzODQyNzg2IzIxOTU4MjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference\",\"datePublished\":\"2020-11-24T21:08:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\\\/\"},\"wordCount\":318,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTgzOCMzODQyNzg2IzIxOTU4MjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\\\/\",\"name\":\"Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTgzOCMzODQyNzg2IzIxOTU4MjQ=\",\"datePublished\":\"2020-11-24T21:08:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTgzOCMzODQyNzg2IzIxOTU4MjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTgzOCMzODQyNzg2IzIxOTU4MjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/","og_locale":"en_US","og_type":"article","og_title":"Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","og_description":"FOSTER CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on Wednesday, December 2, 2020 at 1:50pm ET. A live webcast of the fireside chat can be accessed through the Investors &amp; Media section of the Company\u2019s website at http:\/\/investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About Vaxcyte Vaxcyte is a next-generation vaccine company seeking to improve &hellip; Continue reading \"Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T21:08:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgzOCMzODQyNzg2IzIxOTU4MjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference","datePublished":"2020-11-24T21:08:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/"},"wordCount":318,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgzOCMzODQyNzg2IzIxOTU4MjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/","name":"Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgzOCMzODQyNzg2IzIxOTU4MjQ=","datePublished":"2020-11-24T21:08:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgzOCMzODQyNzg2IzIxOTU4MjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTgzOCMzODQyNzg2IzIxOTU4MjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-present-at-evercore-isi-3rd-annual-healthconx-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388035"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388035\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}